A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 [casopitant] (10mg and 30mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Casopitant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Oct 2010 Actual initiation date changed from 1 Mar 2006 to 1 May 2006 as reported by ClinicalTrials.gov.
- 01 Oct 2010 Actual end date ( Jul 2007) added as reported by ClinicalTrials.gov.
- 07 Dec 2007 Status changed from in progress to completed.